|
|
Blood, 1 October 2004, Vol. 104, No. 7, pp. 2081-2083.
Prepublished online as a Blood First Edition Paper on May 4, 2004; DOI 10.1182/blood-2004-02-0715.
 Previous Article | Next Article 
Submitted February 26, 2004
Accepted April 15, 2004
Identification of novel mutations in ADAMTS13 in an adult patient with congenital thrombotic thrombocytopenic purpura
Toshihiro Uchida, Hideo Wada, Minoru Mizutani, Miho Iwashita, Hiroaki Ishihara, Toshiro Shibano, Misako Suzuki, Yumiko Matsubara, Kenji Soejima, Masanori Matsumoto, Yoshihiro Fujimura, Yasuo Ikeda, and Mitsuru Murata*
New Product Research Laboratories II, Daiichi Pharmaceutical Co. Ltd., Tokyo, Japan
Department of Laboratory Medicine, Mie University School of Medicine, Mie, Japan
Department of Internal Medicine, Yamada Red Cross Hospital, Watarai-gun, Japan
Department of Medicine, Keio University, Tokyo, Japan
First Research Department, The Chemo-Sero-Therapeutic Research Institute, Kumamoto, Japan
Department of Blood Transfusion, Nara Medical University, Nara, Japan
* Corresponding author; email: murata{at}sc.itc.keio.ac.jp.
Congenital thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS) is associated with an inherited von Willebrand factor-cleaving protease (ADAMTS13) deficiency. In this study, we identified novel mutations in the ADAMTS13 gene in a patient with TTP. The patient was a 51-year old Japanese male, who exhibited TTP symptoms at frequent intervals. The ADAMTS13 activity during acute episodes was less than 3% that of normal. The enzyme activities of the patient's father and mother were both 46%, and both parents were asymptomatic. Genetic analysis revealed that the patient was a compound heterozygote for two mutations. One mutation was a missense mutation in the metalloprotease domain (A250V, exon7), and the other was a guanine to adenine substitution at the 5'-end of intron 3 (intron 3 G/A). In vitro expression studies revealed that the A250V mutation markedly reduced ADAMTS13 activity and the intron 3 G/A mutation caused abnormal mRNA synthesis.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
H. B. Feys, I. Pareyn, R. Vancraenenbroeck, M. De Maeyer, H. Deckmyn, C. Van Geet, and K. Vanhoorelbeke
Mutation of the H-bond acceptor S119 in the ADAMTS13 metalloprotease domain reduces secretion and substrate turnover in a patient with congenital thrombotic thrombocytopenic purpura
Blood,
November 19, 2009;
114(21):
4749 - 4752.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Galbusera, M. Noris, and G. Remuzzi
Inherited thrombotic thrombocytopenic purpura
Haematologica,
February 1, 2009;
94(2):
166 - 170.
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Garagiola, C. Valsecchi, S. Lavoretano, H. Oren, M. Bohm, and F. Peyvandi
Nonsense-mediated mRNA decay in the ADAMTS13 gene caused by a 29-nucleotide deletion
Haematologica,
November 1, 2008;
93(11):
1678 - 1685.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Plaimauer, J. Fuhrmann, G. Mohr, W. Wernhart, K. Bruno, S. Ferrari, C. Konetschny, G. Antoine, M. Rieger, and F. Scheiflinger
Modulation of ADAMTS13 secretion and specific activity by a combination of common amino acid polymorphisms and a missense mutation
Blood,
January 1, 2006;
107(1):
118 - 125.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Zhou, L. Dong, D. Ginsburg, E. E. Bouhassira, and H.-M. Tsai
Enzymatically Active ADAMTS13 Variants Are Not Inhibited by Anti-ADAMTS13 Autoantibodies: A NOVEL THERAPEUTIC STRATEGY?
J. Biol. Chem.,
December 2, 2005;
280(48):
39934 - 39941.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. De Cristofaro, F. Peyvandi, R. Palla, S. Lavoretano, R. Lombardi, G. Merati, F. Romitelli, E. Di Stasio, and P. M. Mannucci
Role of Chloride Ions in Modulation of the Interaction between von Willebrand Factor and ADAMTS-13
J. Biol. Chem.,
June 17, 2005;
280(24):
23295 - 23302.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
